Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

NCT07295223 on ClinicalTrials.gov · last registry update 2026-01-05

A small phase 3 — 44 participants, against a typical 424. Its estimated completion date, August 2026, has passed with no update to the record. Primary outcome, as filed: Inflammatory markers (high-sensitivity PCR). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Instituto Mexicano del Seguro Social
Sponsor type: Other Gov
Enrollment: 44
Started: 2025-12-30
Primary completion: 2026-08 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Inflammatory markers (high-sensitivity PCR)

Conditions studied

Acute Myocardial Infarction With ST Elevation

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.